<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515213</url>
  </required_header>
  <id_info>
    <org_study_id>2016-3022</org_study_id>
    <nct_id>NCT03515213</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease</brief_title>
  <official_title>A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to study the safety and efficacy of fenofibrate, an&#xD;
      FDA-approved drug for high cholesterol and/or elevated triglyerides (fats), as a treatment&#xD;
      for Huntington's disease (HD). Subjects who meet the entry criteria will be randomized (3:1)&#xD;
      to either 145mg of fenofibrate or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 27, 2017</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PGC-1alpha from Baseline to Month 6</measure>
    <time_frame>Baseline, 1 month, 2 months, 3 months, 4 months, 5 months and 6 months</time_frame>
    <description>Change in PGC-1alpha from Baseline to Month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fenofibrate level from Baseline to Month 6</measure>
    <time_frame>Baseline, 1 month, 2 months, 3 months, 4 months, 5 months and 6 months</time_frame>
    <description>Change in Fenofibrate level from Baseline to Month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Motor Scores from Baseline to Month 6</measure>
    <time_frame>Baseline, 3 months, and 6 months</time_frame>
    <description>Unified Huntington Disease Rating Scale (UHDRS) Motor (total score range 0-124 where higher score = greater impairment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cognition Scores from Baseline to Month 6</measure>
    <time_frame>Baseline, 3 months, and 6 months</time_frame>
    <description>Montreal Cognitive Assessment (total score range 0-30, higher score = less impairment), Stroop Word (cognitive interference measure, calculated interference score where higher = better performance), and Benton Judgement of Line Orientation (test of spatial thinking, total score range 0-30, higher score = better performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Independence Assessment Scores from Baseline to Month 6</measure>
    <time_frame>Baseline, 3 months, and 6 months</time_frame>
    <description>Unified Huntington Disease Rating Scale (UHDRS) Independence Scale (total score range 0-100 where 100 = 100% independent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment Scores from Baseline to Month 6</measure>
    <time_frame>Baseline, 3 months, and 6 months</time_frame>
    <description>Clinical Global Impression (CGI-I); (total score range 1-7 where higher score = greater impairment), and Unified Huntington Disease Rating Scale (UHDRS) Total Functional Capacity Assessment ( total score range 0-13, higher score = less impairment)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>145mg of fenofibrate</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  An adult of either sex, ages 25-85 inclusive,&#xD;
&#xD;
          -  Have proficiency with written and spoken English and corrected vision or hearing to&#xD;
             complete the cognitive testing,&#xD;
&#xD;
          -  Are able to give informed consent,&#xD;
&#xD;
          -  Have good overall health status with no known problems anticipated over the course of&#xD;
             the trial,&#xD;
&#xD;
          -  Have a diagnosis of HD supported by positive gene test within the past 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other major neurological disease [e.g., multiple sclerosis, parkinson's disease,&#xD;
             cortical stroke, etc]&#xD;
&#xD;
          -  Clinically significant hepatic or renal disease,&#xD;
&#xD;
          -  Current or recent (&lt; 1 month) use of dopamine blocking agents such as tetrabenazine,&#xD;
             anticonvulsants, neuroleptics, HAART, antiemetics, and antipsychotics for any reason,&#xD;
&#xD;
          -  Current use of Warfarin (Coumadin). Enrollment in another investigational drug study&#xD;
             within the prior three months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Hermanowicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie Thompson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

